Oragenics to License Sigyn’s CardioDialysis for TBI Inflammation

Event summary

  • Oragenics signed a non-binding LOI to license Sigyn’s CardioDialysis™ for TBI and neurodegenerative diseases.
  • The deal includes 3.25M shares of restricted preferred stock and a 3% royalty on future sales.
  • CardioDialysis™ targets systemic inflammation, complementing Oragenics’ ONP-002, which addresses neuroinflammation.
  • Closing expected within 90 days, subject to due diligence and regulatory approvals.

The big picture

Oragenics is expanding its TBI treatment platform by integrating Sigyn’s blood purification technology, addressing a critical gap in the market for systemic inflammation management. This move aligns with broader trends in biotech toward multi-modal therapeutic approaches for complex neurological conditions. The deal underscores the growing emphasis on extracorporeal therapies in treating inflammatory disorders.

What we're watching

Execution Risk
Whether Oragenics can secure regulatory approvals and finalize the deal within the 90-day window.
Clinical Synergy
How the combination of ONP-002 and CardioDialysis™ will impact TBI treatment outcomes.
Market Positioning
The pace at which Oragenics can establish itself as the sole provider of dual-modality TBI therapies.